The Conversation (0)
Apr. 29, 2013 06:48PM PST
Radius Health Inc (NASDAQ:RDUS) announced that it has completed its $43 million equity financing, which will be used to support the advancement of the company’s lead asset, BA058, a bone-building compound that will treat patients with osteoporosis.
Radius Health Inc (NASDAQ:RDUS) announced that it has completed its $43 million equity financing, which will be used to support the advancement of the company’s lead asset, BA058, a bone-building compound that will treat patients with osteoporosis.
As quoted in the press release:
Mr. Wyzga continued, “Our recently reported interim blinded safety data for clinical fractures occurring in the Phase 3 trial and the completion of enrollment in both the subcutaneous Phase 3 and the short-wear time patch Phase 2 trials demonstrate solid progress toward our goal of commercializing this compound. Osteoporosis is a large market. Currently available treatments do not adequately serve the needs of patients, especially those at high risk of fracture.
Click here to read the full Radius Health Inc (NASDAQ:RDUS) press release.
